Literature DB >> 2553625

Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages.

J Mauel1, T Van Pham, B Kreis, J Bauer.   

Abstract

Peritoneal and bone marrow-derived macrophages of the C57BL/6 and DBA/2 mouse strains were exposed in vitro to increasing concentrations of the bacterial lysate Broncho-Vaxom (BV), in the presence or absence of macrophage-activating factor (MAF)-rich media. Two metabolic pathways and two functional activities of the macrophages were studied. First, oxidative metabolism was found to increase sharply in macrophages incubated with BV, as measured by the catabolism of glucose via the hexose monophosphate shunt pathway, and by the production of the superoxide anion (O2-). Both effects were further increased by co-stimulation of macrophages with MAF. Second, exposure to BV together with MAF (or with recombinant murine interferon-gamma) led to acquisition by macrophages of the capacity to destroy the intracellular parasite Leishmania enriettii; such activated macrophages were also lytic towards P815 mastocytoma indicator target cells. These cytotoxic properties failed to develop in the absence of MAF. The BV-dependent increase in metabolic and functional activities was of the same magnitude as that induced by incubation of macrophages with 10 ng/ml of bacterial lipopolysaccharide (LPS). Residual contamination of BV by endotoxin was however much lower. In addition, polymyxin B, a LPS inhibitor, blocked the effect of LPS without significantly affecting macrophage stimulation by BV. These experiments indicate that BV can markedly stimulate macrophage metabolic and functional parameters that are important for host defense against pathogens and tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553625     DOI: 10.1016/0192-0561(89)90149-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  10 in total

1.  Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.

Authors:  R Keul; M Roth; E Papakonstantinou; M Nauck; A P Perruchoud; L H Block
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

2.  Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.

Authors:  D Alecsandru; L Valor; S Sánchez-Ramón; J Gil; J Carbone; J Navarro; J Rodríguez; C Rodríguez-Sainz; E Fernández-Cruz
Journal:  Clin Exp Immunol       Date:  2011-04       Impact factor: 4.330

3.  Presence of hsp65 in bacterial extracts (OM-89): a possible mediator of orally-induced tolerance?

Authors:  B S Polla; S Baladi; K Fuller; G Rook
Journal:  Experientia       Date:  1995-08-16

4.  Changes in cytokine and nitric oxide secretion by rat alveolar macrophages after oral administration of bacterial extracts.

Authors:  E Broug-Holub; J H Persoons; K Schornagel; G Kraal
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom.

Authors:  K T Kassabov; J N Stoychkov
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  [Not Available].

Authors:  M D Gutiérrez-Tarango; A Berber
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

Review 7.  Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development.

Authors:  Samuel T Pasco; Juan Anguita
Journal:  Cells       Date:  2020-09-16       Impact factor: 6.600

8.  Effect of OM-85 BV on reducing bronchiectasis exacerbation in Chinese patients: the iPROBE study.

Authors:  Jinming Gao; Lun Li; Nan Jiang; Ying Liao; Lingfei Kong; Yuanlin Song; Jinfu Xu; Jie Cao; Yuping Li; Chengli Que; Roy A Pleasants
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

9.  Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art.

Authors:  Fernando De Benedetto; Gianfranco Sevieri
Journal:  Multidiscip Respir Med       Date:  2013-05-22

10.  Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance.

Authors:  Gianmarco Troiano; Gabriele Messina; Nicola Nante
Journal:  J Prev Med Hyg       Date:  2021-07-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.